Published in Nature on January 13, 2010
Targeting MET in cancer: rationale and progress. Nat Rev Cancer (2012) 6.43
The promise and peril of chemical probes. Nat Chem Biol (2015) 2.64
Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer (2012) 2.35
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell (2011) 2.11
Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer (2013) 1.92
ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal (2010) 1.91
A public-private partnership to unlock the untargeted kinome. Nat Chem Biol (2013) 1.83
A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. Nat Chem Biol (2014) 1.76
Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A (2010) 1.75
Deciphering the structural basis of eukaryotic protein kinase regulation. PLoS Biol (2013) 1.75
Protein tyrosine phosphatases--from housekeeping enzymes to master regulators of signal transduction. FEBS J (2013) 1.68
Dynamically committed, uncommitted, and quenched states encoded in protein kinase A revealed by NMR spectroscopy. Proc Natl Acad Sci U S A (2011) 1.65
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res (2011) 1.53
Activation pathway of Src kinase reveals intermediate states as targets for drug design. Nat Commun (2014) 1.48
Differential hydrogen/deuterium exchange mass spectrometry analysis of protein-ligand interactions. Expert Rev Proteomics (2011) 1.45
Hydrophobic Core Variations Provide a Structural Framework for Tyrosine Kinase Evolution and Functional Specialization. PLoS Genet (2016) 1.43
Targeting the disordered C terminus of PTP1B with an allosteric inhibitor. Nat Chem Biol (2014) 1.40
Targeting protein lipidation in disease. Trends Mol Med (2012) 1.37
Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat Biotechnol (2013) 1.33
Aurora kinase inhibitors as anticancer molecules. Biochim Biophys Acta (2010) 1.33
Myristoylation and membrane binding regulate c-Src stability and kinase activity. Mol Cell Biol (2010) 1.33
Mechanisms of drug resistance in kinases. Expert Opin Investig Drugs (2011) 1.29
The GIST paradigm: lessons for other kinase-driven cancers. J Pathol (2010) 1.26
Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? ACS Chem Biol (2014) 1.23
Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications. Drug Discov Today (2013) 1.13
Biology-driven cancer drug development: back to the future. BMC Biol (2010) 1.12
Allosteric interactions between the myristate- and ATP-site of the Abl kinase. PLoS One (2011) 1.12
Structural basis of p38α regulation by hematopoietic tyrosine phosphatase. Nat Chem Biol (2011) 1.11
Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. J Cell Mol Med (2012) 1.10
Using NMR to study fast dynamics in proteins: methods and applications. Curr Opin Pharmacol (2010) 1.09
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep (2015) 1.07
Ten things you should know about protein kinases: IUPHAR Review 14. Br J Pharmacol (2015) 1.06
Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases. PLoS Comput Biol (2011) 1.06
Structure of a Ca2+-myristoyl switch protein that controls activation of a phosphatidylinositol 4-kinase in fission yeast. J Biol Chem (2011) 1.05
NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors. Proc Natl Acad Sci U S A (2013) 1.03
Optimizing combination therapies with existing and future CML drugs. PLoS One (2010) 1.01
Bioinformatics and variability in drug response: a protein structural perspective. J R Soc Interface (2012) 1.01
Structure and dynamic regulation of Abl kinases. J Biol Chem (2013) 1.01
Blind prediction of HIV integrase binding from the SAMPL4 challenge. J Comput Aided Mol Des (2014) 0.99
The ins and outs of selective kinase inhibitor development. Nat Chem Biol (2015) 0.98
A myristoyl/phosphoserine switch controls cAMP-dependent protein kinase association to membranes. J Mol Biol (2011) 0.98
A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A. ACS Chem Biol (2012) 0.98
Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Oncol (2014) 0.97
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochem Pharmacol (2010) 0.96
Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor. PLoS One (2012) 0.96
Dynamics-Driven Allostery in Protein Kinases. Trends Biochem Sci (2015) 0.96
The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL. Cancer Res (2012) 0.95
Small molecule regulation of protein conformation by binding in the Flap of HIV protease. ACS Chem Biol (2013) 0.94
Dynamic architecture of a protein kinase. Proc Natl Acad Sci U S A (2014) 0.94
Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis. PLoS One (2012) 0.94
Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. Leukemia (2010) 0.93
c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells. Cell Rep (2015) 0.93
Small molecule probes of cellular pathways and networks. ACS Chem Biol (2010) 0.92
Role of Abl in airway hyperresponsiveness and airway remodeling. Respir Res (2013) 0.92
The ins and outs of bcr-abl inhibition. Genes Cancer (2012) 0.91
Carboxyl-group footprinting maps the dimerization interface and phosphorylation-induced conformational changes of a membrane-associated tyrosine kinase. Mol Cell Proteomics (2011) 0.91
Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study. PLoS One (2013) 0.91
Overcoming Chemical, Biological, and Computational Challenges in the Development of Inhibitors Targeting Protein-Protein Interactions. Chem Biol (2015) 0.91
Structure, regulation, signaling, and targeting of abl kinases in cancer. Genes Cancer (2012) 0.90
Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells. Protein Cell (2013) 0.90
Enhanced SH3/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitors. J Biol Chem (2013) 0.90
Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Neuro Oncol (2011) 0.89
BCR-ABL1 kinase: hunting an elusive target with new weapons. Chem Biol (2011) 0.89
Conformational equilibrium of N-myristoylated cAMP-dependent protein kinase A by molecular dynamics simulations. Biochemistry (2012) 0.88
Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines. PLoS One (2015) 0.88
RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth. PLoS One (2012) 0.88
p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system. PLoS One (2011) 0.88
Understanding resistance to combination chemotherapy. Drug Resist Updat (2012) 0.88
Targeting RAF-MEK-ERK kinase-scaffold interactions in cancer. Nat Med (2013) 0.87
Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells. Blood (2011) 0.87
Partial cooperative unfolding in proteins as observed by hydrogen exchange mass spectrometry. Int Rev Phys Chem (2013) 0.87
Development of an effective therapy for chronic myelogenous leukemia. Cancer J (2011) 0.87
Crk and ABI1: binary molecular switches that regulate abl tyrosine kinase and signaling to the cytoskeleton. Genes Cancer (2012) 0.86
Role of c-Abl tyrosine kinase in smooth muscle cell migration. Am J Physiol Cell Physiol (2014) 0.86
The Philadelphia chromosome in leukemogenesis. Chin J Cancer (2016) 0.86
The energy landscape analysis of cancer mutations in protein kinases. PLoS One (2011) 0.86
Molecular insight into the conformational dynamics of the Elongin BC complex and its interaction with HIV-1 Vif. J Mol Biol (2010) 0.86
Modeling of molecular interaction between apoptin, BCR-Abl and CrkL--an alternative approach to conventional rational drug design. PLoS One (2012) 0.85
Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface. J Biol Chem (2013) 0.85
Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro. Acta Pharmacol Sin (2014) 0.85
p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia. Haematologica (2011) 0.85
Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors. Curr Hematol Malig Rep (2015) 0.84
Detection of secondary binding sites in proteins using fragment screening. Proc Natl Acad Sci U S A (2015) 0.83
c-Abl tyrosine kinase regulates cytokinesis of human airway smooth muscle cells. Am J Respir Cell Mol Biol (2014) 0.83
Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class. J Med Chem (2011) 0.83
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I. BMC Cancer (2012) 0.83
Direct detection of structurally resolved dynamics in a multiconformation receptor-ligand complex. J Am Chem Soc (2011) 0.83
Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics. PLoS Comput Biol (2015) 0.83
Critical role of actin-associated proteins in smooth muscle contraction, cell proliferation, airway hyperresponsiveness and airway remodeling. Respir Res (2015) 0.83
Multifunctional Abl kinases in health and disease. J Cell Sci (2016) 0.83
Expanding the diversity of allosteric bcr-abl inhibitors. J Med Chem (2010) 0.83
Targeted inhibition of kinases in cancer therapy. Mt Sinai J Med (2010) 0.82
Abl family kinases regulate endothelial barrier function in vitro and in mice. PLoS One (2013) 0.82
A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1. Proc Natl Acad Sci U S A (2014) 0.82
SPLINTS: small-molecule protein ligand interface stabilizers. Curr Opin Struct Biol (2016) 0.82
Biophysics in drug discovery: impact, challenges and opportunities. Nat Rev Drug Discov (2016) 0.81
The Emerging Role of ABL Kinases in Solid Tumors. Trends Cancer (2015) 0.81
Neutralizing positive charges at the surface of a protein lowers its rate of amide hydrogen exchange without altering its structure or increasing its thermostability. J Am Chem Soc (2010) 0.81
Two-state dynamics of the SH3-SH2 tandem of Abl kinase and the allosteric role of the N-cap. Proc Natl Acad Sci U S A (2013) 0.81
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 20.30
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03
Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 11.83
A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature (1994) 11.50
A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A (1995) 10.25
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med (2001) 7.88
Three-dimensional structure of the tyrosine kinase c-Src. Nature (1997) 7.62
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell (2003) 5.71
Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell (2003) 5.44
Hydrogen exchange mass spectrometry for the analysis of protein dynamics. Mass Spectrom Rev (2005) 5.23
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res (2002) 4.19
Di- and triphosphopyridine nucleotide isocitric dehydrogenases in yeast. J Biol Chem (1951) 3.73
Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J (2005) 3.58
A myristoyl/phosphotyrosine switch regulates c-Abl. Cell (2003) 3.48
KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II. J Biol Chem (1990) 3.40
Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem Biol (2004) 3.30
BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem (2002) 3.05
Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol (2006) 2.96
Semi-automated data processing of hydrogen exchange mass spectra using HX-Express. J Am Soc Mass Spectrom (2006) 2.92
Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov (2007) 2.40
High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein Sci (2005) 2.32
High-speed and high-resolution UPLC separation at zero degrees Celsius. Anal Chem (2008) 2.27
Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem (2008) 2.09
Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood (2007) 1.85
Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res (2004) 1.79
Conformational disturbance in Abl kinase upon mutation and deregulation. Proc Natl Acad Sci U S A (2009) 1.47
Nucleotide sequence of testis-derived c-abl cDNAs: implications for testis-specific transcription and abl oncogene activation. Proc Natl Acad Sci U S A (1987) 1.31
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci U S A (2006) 1.30
A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood (2004) 1.29
Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells. Cancer Res (2006) 1.28
Efficient uniform isotope labeling of Abl kinase expressed in Baculovirus-infected insect cells. J Biomol NMR (2005) 1.08
N-myristoylated c-Abl tyrosine kinase localizes to the endoplasmic reticulum upon binding to an allosteric inhibitor. J Biol Chem (2009) 1.04
Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. Cancer (2008) 0.99
Development of thioquinazolinones, allosteric Chk1 kinase inhibitors. Bioorg Med Chem Lett (2008) 0.95
Protein NMR in biomedical research. Cell Mol Life Sci (2004) 0.91
Disease progression in a murine model of bcr/abl leukemogenesis. Leuk Lymphoma (1993) 0.81
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Reprogramming of human somatic cells to pluripotency with defined factors. Nature (2007) 30.84
Disease-specific induced pluripotent stem cells. Cell (2008) 16.95
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Selective blockade of microRNA processing by Lin28. Science (2008) 14.39
Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell (2010) 14.18
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol (2009) 11.18
Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet (2009) 10.54
Somatic coding mutations in human induced pluripotent stem cells. Nature (2011) 9.50
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26
Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell (2009) 8.97
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99
Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat Biotechnol (2009) 7.59
Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature (2007) 7.55
Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature (2011) 7.43
Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell (2011) 7.41
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature (2009) 7.05
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80
Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat Biotechnol (2009) 6.76
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science (2011) 6.75
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res (2008) 6.71
KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science (2003) 6.60
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
A unifying model for mTORC1-mediated regulation of mRNA translation. Nature (2012) 6.44
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature (2010) 6.06
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res (2005) 5.98
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell (2009) 5.97
HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell (2002) 5.71
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell (2003) 5.71
The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature (2012) 5.61
The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. Dev Cell (2008) 5.58
Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet (2010) 5.37
Hydrogen exchange mass spectrometry for the analysis of protein dynamics. Mass Spectrom Rev (2005) 5.23
The promise of induced pluripotent stem cells in research and therapy. Nature (2012) 5.05
Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol (2006) 5.03
Generation of induced pluripotent stem cells from human blood. Blood (2009) 4.92
Generation of human-induced pluripotent stem cells. Nat Protoc (2008) 4.85
mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science (2010) 4.81
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci U S A (2008) 4.80
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Attenuated cold sensitivity in TRPM8 null mice. Neuron (2007) 4.73
miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med (2010) 4.71
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell (2009) 4.69
The Lin28/let-7 axis regulates glucose metabolism. Cell (2011) 4.65
Mitogenic influence of human R-spondin1 on the intestinal epithelium. Science (2005) 4.58
Derivation of embryonic germ cells and male gametes from embryonic stem cells. Nature (2003) 4.56
Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell (2002) 4.56
Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature (2007) 4.54
Determinants of microRNA processing inhibition by the developmentally regulated RNA-binding protein Lin28. J Biol Chem (2008) 4.40
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res (2011) 4.22
Chromatin-modifying enzymes as modulators of reprogramming. Nature (2012) 4.22
Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature (2009) 4.14
Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol (2011) 3.97
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet (2004) 3.96
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature (2009) 3.93
Mesenchymal stem cell-mediated functional tooth regeneration in swine. PLoS One (2006) 3.91
White Collar-1, a circadian blue light photoreceptor, binding to the frequency promoter. Science (2002) 3.85
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A (2006) 3.83
Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet (2013) 3.83
Lin28: A microRNA regulator with a macro role. Cell (2010) 3.39
Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology (2010) 3.36
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer (2007) 3.36
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med (2010) 3.26
Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat Biotechnol (2011) 3.25
R-Spondin1 regulates Wnt signaling by inhibiting internalization of LRP6. Proc Natl Acad Sci U S A (2007) 3.24
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One (2011) 3.23
Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility. Nat Chem Biol (2008) 3.23
Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol (2008) 3.18
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res (2010) 3.16
The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol (2010) 3.15
Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell (2010) 3.08